Core Viewpoint - NeurAxis, Inc. is set to release its financial results for the first quarter of 2025 on May 12, 2025, before market open, followed by a conference call to discuss the results [1]. Financial Results Announcement - The financial results will cover the period ended March 31, 2025 [1]. - A conference call is scheduled for May 12, 2025, at 9:00 a.m. Eastern Time to review the results [1]. Conference Call Details - Interested parties can access the conference call via a live webcast available on the Company's Investor Relations website [2]. - Participants can submit questions through the webcast portal or via email [2]. - Call-in participants must register to receive dial-in information and a unique PIN [3]. Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4]. - The company is advancing its proprietary IB-Stim™ therapy, which is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 [4]. - Additional clinical trials for PENFS technology are ongoing for various pediatric and adult conditions with significant unmet healthcare needs [4].

Core Viewpoint - BioSig Technologies, Inc. has entered into a Letter of Intent to merge with Streamex Exchange Corporation in an all-stock transaction, aiming to bring a real-world asset tokenization company public on Nasdaq [1][2] Proposed Transaction Highlights - The merger will create a platform for real-world asset tokenization, focusing on commodities, enhancing investment processes, and increasing capital availability for companies and investors [5][6] - Streamex aims to revolutionize commodity finance by bringing commodity markets on-chain, leveraging advanced financial technologies and blockchain transparency [7] Company Background - Streamex is a real-world asset tokenization company targeting the commodities sector, led by experienced executives from financial, commodities, and blockchain industries [6] - The company believes in the future of finance through tokenization and decentralized markets, aiming to enhance liquidity and accessibility for investors [7] Leadership Changes - Post-merger, Henry McPhie will become the CEO, and Morgan Lekstrom will serve as Chairman of the Board, with Anthony Amato remaining on the Board [12] - Strategic advisors with significant industry experience will be added to the Board, including Frank Giustra, Mathew August, and Mitchell Williams [12] Ownership Structure - After the merger, former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the combined company, while current BioSig stakeholders will hold the remaining equity [13]

Core Insights - Integra LifeSciences Holdings Corporation reported total revenues of $382.7 million for Q1 2025, reflecting a 3.7% increase on a reported basis but a 3.5% decline on an organic basis compared to the previous year [3][13] - The company experienced a GAAP net loss of $(25.3) million, or $(0.33) per diluted share, compared to a net loss of $(3.3) million, or $(0.04) per diluted share, in Q1 2024 [5][13] - Adjusted EBITDA for Q1 2025 was $63.6 million, representing 16.6% of revenue, down from $71.8 million, or 19.5% of revenue, in the prior year [4][29] Financial Performance - Total revenues for the Codman Specialty Surgical segment were $280.7 million, showing reported growth of 9.4% but an organic decline of 1.1% compared to Q1 2024 [6] - The Tissue Technologies segment reported revenues of $102.0 million, a decline of 9.3% on a reported basis and 9.1% organically compared to the same quarter last year [7] - The company generated cash flow from operations of $(11.3) million in the quarter, with total balance sheet debt at $1.85 billion and net debt at $1.58 billion, resulting in a consolidated total leverage ratio of 4.3x [7][8] Outlook - For Q2 2025, the company expects reported revenues between $390 million and $400 million, indicating a decline of 6.8% to 4.4% on a reported basis and 7.5% to 5.1% organically [9] - The full-year 2025 revenue guidance remains at $1.650 billion to $1.715 billion, representing reported growth of 2.4% to 6.5% and organic growth of 0.4% to 4.4% [10] - Adjusted EPS guidance for 2025 has been reduced to a range of $2.19 to $2.29 per share, accounting for an estimated impact of $(0.22) per share due to new tariffs [10] Segment Insights - Sales in the Neurosurgery segment declined by 4.7% on an organic basis, attributed to shipping holds across several product lines [14] - Instruments sales grew by 15.1% on an organic basis due to strong demand and favorable prior year comparisons [14] - The ENT segment reported significant revenue growth driven by the Acclarent acquisition, while private label sales decreased by 13.3% due to component supply delays [14]

Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that it has launched the MyoVista InsightsTM platform and related early adopter program for select reference sites. MyoVista Insights is a cloud-native next-generation ECG Management System designed to enhance ...

Core Insights - Boston Scientific Corporation will participate in two investor conferences in May 2025 [1] Group 1: Upcoming Events - On May 13, 2025, Dan Brennan and Joe Fitzgerald will engage in a 30-minute Q&A session at Bank of America's 2025 Health Care Conference starting at 8:00 a.m. PT / 11:00 a.m. ET [2] - On May 28, 2025, Mike Mahoney and Ken Stein will participate in a 50-minute Q&A session at Bernstein's 41st Annual Strategic Decisions Conference starting at 8:00 a.m. ET [3] Group 2: Webcast Information - A live webcast and replay for each event will be available at Boston Scientific's investor relations website, with the replay accessible approximately one hour after the event concludes [4] Group 3: Company Overview - Boston Scientific is a global leader in medical technology, transforming lives through innovative solutions that improve patient health and reduce healthcare costs [5]

Financial Data and Key Metrics Changes - Revenues grew 6% or 0.9% organically, which was below expectations, primarily due to market dynamics in Life Sciences and a slower return to normal levels in blood culture testing [6][12] - Adjusted gross margins increased to 54.9%, up 190 basis points year over year, driven by BD Excellence initiatives [7][26] - Adjusted diluted EPS was $3.35, reflecting a growth of 5.7% [26][30] Business Line Data and Key Metrics Changes - Biosciences faced challenges due to reduced global research funding, impacting instrument sales, while reagent sales continued to grow [9][11] - Diagnostics experienced softness in the Bactech Blood Culture business, with a slower recovery in testing levels [11][12] - Farm Systems returned to growth in Q2, driven by biologics and increased orders for GLP-1s [13][24] Market Data and Key Metrics Changes - Total company organic growth was led by the U.S., Greater Asia (excluding China), and Latin America, while EMEA declined and China saw a double-digit decrease [24] - The company adjusted its full-year revenue guidance to expect 3% to 3.5% organic growth due to market dynamics [12][29] Company Strategy and Development Direction - The company is focused on navigating the near-term environment while positioning itself for long-term value through strategic investments [6][19] - BD plans to invest $2.5 billion in U.S. manufacturing over the next five years to strengthen its position in the healthcare system [15][18] - The separation process for the Biosciences and Diagnostics business is on track, with strong interest in the assets [19][85] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over the volatility in research funding and its impact on sales, particularly in the Life Sciences segment [6][77] - The company remains committed to mitigating tariff impacts and expects to absorb $90 million in tariff expenses for FY 2025 [17][30] - Future guidance includes total revenue growth of 7.8% to 8.3% and organic growth of 3% to 3.5% for the remainder of the fiscal year [29][30] Other Important Information - BD Excellence initiatives are seen as a key driver for margin expansion and growth investments in R&D and commercial programs [8][22] - The company is actively managing its supply chain to mitigate tariff impacts and has implemented cost containment measures [18][72] Q&A Session Summary Question: Clarification on tariff impact - The $0.25 EPS impact from tariffs is a net number after mitigation efforts, and the situation remains fluid with ongoing adjustments [33][36] Question: Expectations for organic growth in the second half - The company expects organic growth to improve sequentially, with Q3 around 3% and Q4 expected to exceed 5% due to easier comparisons and key growth drivers [39][51] Question: Breakdown of organic sales growth adjustments - The adjustment reflects known headwinds in China and market-driven factors, with significant impacts from BDB and research spending [54][56] Question: Actions regarding tariffs and mitigation - The company is employing multiple strategies, including inventory positioning and sourcing alternatives, to mitigate tariff impacts [64][66] Question: Confidence in guidance amid market changes - Management acknowledged the challenges but emphasized strong execution on earnings and the ability to navigate macro dynamics effectively [75][82] Question: Update on Life Sciences separation process - The separation remains on schedule with strong interest in the assets, and details will be shared in the summer [85][86]

Q2 FY25 Performance - Revenue reached $5.3 billion, with a 6.0% increase on a currency-neutral (FXN) basis, and a 0.9% increase organically[23] - Adjusted diluted EPS was $3.35, a 5.7% year-over-year increase[23] - Adjusted operating margin improved by 60 bps year-over-year to 24.9%[23] - Operating cash flow year-to-date was $0.9 billion[23] - Free cash flow year-to-date decreased by 44% to $623 million, reflecting planned one-time cash payments[35] Segment Performance - BD Medical revenue was $2.76 billion, up 14.3% FXN and 3.6% organically[23] - BD Life Sciences revenue was $1.247 billion, down 2.4% FXN (all organic)[23] - BD Interventional revenue was $1.264 billion, down 1.1% FXN (all organic)[23] FY25 Guidance - Estimated total company revenue is projected to be approximately $21.8 billion to $21.9 billion[37] - Adjusted revenue growth (FXN) is expected to be 7.8% to 8.3%[37] - Organic revenue growth (FXN) is projected to be 3.0% to 3.5%, which includes absorbing an approximate 175 bps impact from an expected decline in China, as well as Biosciences and Pharmaceutical Systems market dynamics[37] - Adjusted diluted EPS is guided to be $14.06 to $14.34, representing a 7.0% to 9.1% increase compared to $13.14 in FY24, inclusive of an estimated tariff impact of (25¢)[37]

Financial Data and Key Metrics Changes - The company reported Q1 2025 net sales of $88 million, representing a 4% year-over-year growth, despite a tough comparison from Q1 2024 which had 18% growth [5][19] - Adjusted gross profit margin was 84% for the quarter, while GAAP gross margin was 81%, down from 85% in the prior year [21][24] - Adjusted EBITDA was $17 million, or 20% of net sales, compared to $19 million, or 22% of net sales in the prior year [24] - The company ended the quarter with $106 million in cash, an increase of $2 million during the quarter [8][25] Business Line Data and Key Metrics Changes - Surgical sales grew by 16% to $32 million, driven by strong performance from AmnioFect and HelioGen [20] - Wound sales declined by 2% to $56 million, facing challenges due to Medicare reimbursement disruptions [20][12] - The Amneal branded products grew by 22% in Q1, while HelioGen showed sequential growth from a low base [11] Market Data and Key Metrics Changes - The company noted that approximately 25% of its overall business has ASP exposure, which complicates pricing strategies in the current reimbursement environment [15][47] - The ongoing disruption in the private office and associated care settings due to Medicare reimbursement issues has impacted sales, particularly in the wound care segment [6][12] Company Strategy and Development Direction - The company aims to innovate and diversify its product portfolio, focusing on unique product configurations to meet customer needs [10] - Strategic priorities include expanding the surgical market footprint and enhancing customer relationships through programs like Mimetics Connect [16][18] - The company is actively pursuing opportunities for organic and inorganic growth, including potential acquisitions [62] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the delay in Medicare reimbursement reforms but remains committed to advocating for necessary changes [27][28] - The company reiterated its full-year revenue growth outlook to be at least in the high single digits, with expectations for higher growth rates in the latter half of the year [31] - Long-term prospects remain positive, with expectations of resetting top-line growth to low double digits post-reform [31] Other Important Information - The company has contingency plans in place to adapt to the current reimbursement environment and is exploring third-party manufactured products to retain customers [13][15] - Management emphasized the importance of generating clinical evidence to support product use in surgical applications [16] Q&A Session Summary Question: Adjusted gross profit margin expectations - Management confirmed that the adjusted gross profit margin of 84% in Q1 was related to product mix and expected some pressure from ASPs throughout the year [35] Question: Progress on Equifax in Japan - Management indicated that growth in Japan is on track but remains relatively small in overall contribution [37] Question: Overall reimbursement landscape and confidence in future changes - Management expressed frustration over the lack of changes in the reimbursement landscape but remains hopeful for future reforms [42][44] Question: Shifting private office volumes to new products - Management stated that the shift to higher-priced products is a necessary step to protect business but cautioned against expecting significant volume conversion [50][52] Question: Efforts to prepare for a better market environment - Management highlighted the importance of executing their plan, expanding product offerings, and investing in commercial strength and clinical research [60][62] Question: Changes in purchasing patterns due to LCD delays - Management suggested that there may be shifts in purchasing patterns as higher-priced products become more prevalent, but the overall impact remains uncertain [70][74]

FRANKLIN LAKES, N.J., April 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 13, 2025 at 1:00 pm Eastern Time.The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the l ...

Core Insights - Robotic-assisted surgery is becoming essential in modern healthcare, with Intuitive Surgical and Stryker leading the market [1][2] - Both companies are heavily investing in innovation and global expansion, making them attractive for investors [2] Market Position and Differentiation - Intuitive Surgical pioneered robotic surgery with the da Vinci platform, while Stryker entered the market through the acquisition of Mako Surgical [3] - Intuitive holds nearly 80% of global surgical robotics volume, contrasting with Stryker's focus on orthopedic robotics with over 1.5 million Mako procedures [4] Revenue & Growth Trends - Intuitive's Q1 2025 revenues increased by 19% to $2.25 billion, with da Vinci procedures growing by 17% [5] - Stryker's MedSurg/Neurotechnology sales rose by 10.6% to $3.89 billion in Q4 2024, while Orthopaedics climbed by 10.8% to $2.55 billion [5] - The global robotic surgery market is projected to grow at a CAGR of 16.5% through 2029, driven by minimally invasive trends and aging populations [6] Estimates Comparison for ISRG & SYK - Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 7.1% respectively [7] - Zacks Consensus Estimate for Stryker's 2025 sales and EPS implies a year-over-year improvement of 8.6% and 10.4% respectively [10] Innovation Driving Growth - Intuitive Surgical is investing in next-generation platforms like the Ion endoluminal system for robotic bronchoscopy [12] - Stryker is enhancing its Mako SmartRobotics suite with AI-driven 3D CT planning and AccuStop haptic feedback [13] Price Performance & Valuation - Year-to-date price performance shows ISRG shares have lost 1.5%, while SYK shares have gained 1.8% [15] - Intuitive Surgical's dominance and sustainable revenue growth position it well, while Stryker's innovations fuel growth in the joint-replacement robotics niche [17] Zacks Rank & Style Score - Both companies currently hold a Zacks Rank 3 (Hold), complicating the investment decision [18] - ISRG's style score of 'F' indicates expensive valuation and low growth potential, while SYK's style score of 'C' suggests strong growth prospects [19]